T Cell-based Immunotherapy

T Cell-Based Immunotherapy is a therapeutic strategy within immunopharmacology that harnesses engineered or activated T cells to selectively target and eliminate pathological cells, distinguished from other immunotherapies by its direct reliance on T lymphocyte specificity and cytotoxic function.

3.3K

Publications

287.8K

Citations

22.6K

Authors

3.1K

Institutions

Publications per year

2017–2026

1.4K

Authors

22.6K

  1. SA
    Steven A. Rosenberg

    National Cancer Institute, United States

    67 publications · 26.6K citations

    50

    h-index

  2. CH
    Carl H. June

    University of Pennsylvania, United States

    65 publications · 15.9K citations

    39

    h-index

  3. CM
    Cliona M. Rooney

    Baylor College of Medicine, United States

    56 publications · 9.6K citations

    38

    h-index

  4. HE
    Helen E. Heslop

    Baylor College of Medicine, United States

    48 publications · 9.3K citations

    37

    h-index

  5. MK
    Malcolm K. Brenner

    Baylor College of Medicine, United States

    41 publications · 9.6K citations

    34

    h-index

1–5 of 22.6K

Venues

  1. Blood

    231 publications · 30.6K citations

    90

    h-index

  2. The Journal of Immunology

    JI · 189 publications · 14.4K citations

    67

    h-index

  3. Proceedings of the National Academy of Sciences

    PNAS · 57 publications · 11.3K citations

    46

    h-index

  4. Cancer Research

    72 publications · 7.6K citations

    44

    h-index

  5. OncoImmunology

    117 publications · 6K citations

    44

    h-index

1–5